Significant discrepancies exist when analyzing cancer treatment approaches in the US and Western Europe. The American model, generally characterized by private insurance and a priority on innovation, often leads to swift adoption of cutting-edge therapies, albeit at a significantly higher cost. In contrast, Continental systems frequently rely on st